volume 18, issue 1, P33-37 1997
DOI: 10.2500/108854197778612844
View full text
Has erratum
|
Sign up to set email alerts
|
Share

Abstract: This 12-month, multicenter, open-label study to assess the long-term safety and efficacy of triamcinolone acetonide (TAA) aqueous nasal spray for perennial allergic rhinitis (PAR) symptom relief was a continuation of a 4-week, double-blind study. Patients who received TAA Aqueous (220 micrograms/day) during the 4-week, double-blind study continued with the same treatment for the open label study; those randomized to placebo during the 4-week, double-blind study received TAA Aqueous (220 micrograms/day) for the…

Expand abstract
Editorial notices

Search citation statements

Order By: Relevance

Citation Types

1
4
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals